Finding effective treatments and ultimately

A CURE FOR FRAGILE X SYNDROME

Our Impact to Date

$
0
26,739,564

Direct Investment in Fragile X Research

What is Fragile X Syndrome?

Fragile X syndrome (FXS) is the most common inherited cause of autism and intellectual disabilities. It affects 1 in 4,000 boys and 1 in 6,000 girls worldwide.

Fragile X syndrome occurs when a single gene on the X chromosome shuts down. This gene makes a protein needed for normal brain development. In FXS it does not work properly, the protein is not made, and the brain does not develop as it should.

Learn more about Fragile X syndrome

How Does FRAXA Help?

FRAXA’s mission is to find effective treatments and ultimately a cure for Fragile X syndrome. We directly fund research grants and fellowships at top universities around the world. We partner with biomedical and pharmaceutical companies, large and small, to bridge the gap between research discoveries and actual treatments.

Treatments for Fragile X are likely to help people affected by autism, Alzheimer’s, and other brain disorders.

Donate to FRAXA's mission

Upcoming Events

No event found!

Latest Fragile X News & Updates

Ringing the Bell at the New York Stock Exchange for Fragile X Awareness

FRAXA Research Foundation was honored to be part of the opening bell ringing ceremony at the New York Stock Exchange (NYSE) on July 5, 2018. We were there to raise awareness for Fragile X along side the National Fragile X Foundation. FRAXA President Katie Clapp and Director of Community Relations Dave Bjork were there with over 30 Fragile X family members and friends, including 4 self-advocates. This was a great opportunity to raise awareness of Fragile X on a big stage at an iconic place. The event was also carried live on television on CNBC so this gave FRAXA and Fragile X broad reach around the world.
Read more

Activity-Dependent Translational Profiling in Fragile X Neurons

FRAXA's first-ever grant to researchers at the University of California at Berkeley goes to Dr. Nicholas Ingolia and Dr. J. Wren Kim to analyze the proteomics of Fragile X neurons using a newly developed tool which can distinguish the profiles of neurons that are actively responding to signals.
Read more

Press Release: Tetra Discovery Partners Initiates Phase 2 Trial of BPN14770 in Fragile X Syndrome

Tetra Discovery Partners today announced the initiation of a Phase 2 study of BPN14770 as a potential treatment for Fragile X Syndrome, the most common genetic form of autism. A selective small molecule inhibitor of the phosphodiesterase type-4D (PDE4D) subtype, BPN14770 has shown the ability to improve the quality of connections between neurons and to improve multiple behavioral outcomes in the Fragile X mouse model.
Read more

Current Fragile X Research

Funded by FRAXA Research Foundation

30

Teams actively researching Fragile X

Current Research Grants
FRAXA X - transparentFRAXA X - transparent

27

Pharmaceutical and Biomedical Partners

FRAXA X - transparentFRAXA X - transparent

4

ongoing fragile x clinical trials and studies

Current Clinical Trials & Studies
FRAXA X - transparentFRAXA X - transparent

11

Countries are home to research teams

FRAXA X - transparentFRAXA X - transparent

4

gene therapy and protein replacement studies

Current Studies
FRAXA X - transparentFRAXA X - transparent